-
NewsPublication 2017C.D.C. Panel Recommends a New Shingles Vaccine
In a New York Times report, the Centers for Disease Control and Prevention recommended the …
In a New York Times report, the Centers for Disease Control and Prevention recommended the use of a new vaccine to prevent herpes zoster (“shingles”) among adults in the US. “In an unusually close vote, an advisory panel to the Centers for Disease Control and Prevention on Wednesday recommended the use of a new vaccine to prevent shingles over an older one that was considered less effective. "The decision was made just days after the…
Science/Technology | Infectious Diseases | Health Systems | Policy/Regulation | Economics/Finance | Health/Medicine | North America -
ArticlePublication 2017Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated
This article reports on a clinical trial of the new herpes zoster vaccine (HZ subunit …
This article reports on a clinical trial of the new herpes zoster vaccine (HZ subunit vaccine, HZ/su) among individuals previously vaccinated with the live-attenuated zoster vaccine Zostavax (ZVL; immunity known to wane within 3-7 years) and previously unvaccinated individuals (multicenter study (NCT02581410)). Among a sample of 430 adults age 65+ years, HZ/su induces a strong immune response irrespective of prior vaccination with ZVL. They conclude that HZ/su may be an attractive option to re-vaccinate…
Science/Technology | Health Outcomes | Infectious Diseases | Health/Medicine | North America -
ArticlePublication 2017Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine Co-Administered with Influenza Vaccine in Adults
This article reports on a clinical trial (NCT01954251) of herpes zoster subunit vaccine (HZ/su) co-administered …
This article reports on a clinical trial (NCT01954251) of herpes zoster subunit vaccine (HZ/su) co-administered with a quadrivalent seasonal inactivated influenza vaccine (IIV4) in adults age 50 years and older. Outcome measures were vaccine response rate and antibody response in the intervention compared to control groups. There were 413 subjects in the intervention group and 415 in the control. Antibody response was within statistical limits for similarity between the two groups; no safety concerns were…
Science/Technology | Health Outcomes | Infectious Diseases | Health/Medicine | North America
3 Shown
General Resources
Teaching Resources
Collections
Format
Learner Level
Teaching Topic
General Resources
Teaching Resources
Collections
Format
Learner Level
Teaching Topic